pdf   xlsx method abbreviations

renal cell cancer (RCC), atezolizumab based treatment versus VEGF(R) inhibitor, meta-analysis of study results

Outcome Relative effect 95%CI LoD Trt. better when I2 k (RCT/OBS) Bayesian probability Overall ROB Publication bias Degree of certainty Endpoint importance Published MA

efficacy endpoints 00

deaths (OS) 0.94 [0.70, 1.27]< 10%1 study (1/-)65.8 %NAnot evaluable crucial-
progression or deaths (PFS) 1.05 [0.89, 1.25]< 10%3 studies (3/-)26.5 %lownot evaluable highimportant-
objective responses (ORR) 0.96 [0.63, 1.49]> 10%2 studies (2/-)43.3 %some concernnot evaluable moderatenon important-

safety endpoints 00

AE (any grade) 0.81 [0.11, 5.81]< 10%2 studies (2/-)58.3 %some concernnot evaluable moderatenon important-
AE (grade 3-4) 0.68 [0.29, 1.63]< 189%3 studies (3/-)80.6 %some concernnot evaluable moderatenon important-
AE leading to death (grade 5) 1.69 [0.84, 3.41]< 10%3 studies (3/-)7.3 %lownot evaluable highnon important-
AE leading to treatment discontinuation (any grade) 4.56 [2.23, 9.33]< 10%1 study (1/-)0.0 %NAnot evaluable non important-
SAE (any grade) 1.90 [1.33, 2.71]< 10%1 study (1/-)0.0 %NAnot evaluable non important-
TRAE (any grade) 0.28 [0.12, 0.63]< 10%2 studies (2/-)99.9 %some concernnot evaluable moderatenon important-
TRAE (grade 3-4) 0.27 [0.08, 0.89]< 187%2 studies (2/-)98.4 %some concernnot evaluable moderatenon important-
TRAE leading to death (grade 5) 0.37 [0.06, 2.52]< 10%2 studies (2/-)84.3 %some concernnot evaluable moderatenon important-

TRAE (grade 3-4) endpoints 00

Colitis TRAE (grade 3-4) 0.99 [0.06, 15.86]< 10%2 studies (2/-)50.4 %some concernnot evaluable moderatenon important-
Pneumonitis TRAE (grade 3-4) 0.99 [0.06, 15.86]< 10%2 studies (2/-)50.4 %some concernnot evaluable moderatenon important-

LoD: level of statistical demonstration: Statistically conclusive: statistically significant with a strict control of overall risk of type 1 error (statistically demonstrated), does not take into account the risk of bias; suggested: nominally statistically significant but without a strict control of overall risk of type 1 error; inconclusive: not nominally statistically significant; safety concerns;
Bayesian probability: Bayesian posterior probability of treatment effect (computed with a noninformative prior); ROB: risk of bias; k: number of studies; published MA: number of published meta-analysis on the same topic; degree of certainty adapted from GRADE. Trt. better when: indicates when the relative treatment effect shows that the studied treatment is better than control.



 

- About us - Contact us - Method - RSS Made with in Lyon - Credits - Privacy policy - Licence Creative Commons